Resultados de la búsqueda 151-160 of 3538 for pneumococcal vaccine

  1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma. Rochester, Minn. The purpose of ...

  2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...

  3. Mayo Clinic Digestive Diseases Physician Update - May 2023

    Page 1.

  4. Historia de la gripe (influenza): línea cronológica de brotes y vacunas

    ... vaccine (Vacuna trivalente combinada contra sarampión, paperas y rubéola). JAMA. 1971;218:57. Klein NP. Licensed pertussis vaccine in the United States ...

  5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma. Durvalumab is FDA approved for treatment in lung ...

  6. Historia de la rabia: línea cronológica de brotes y vacunas

    2021; doi:10.1056/NEJMp2034334. Saleh A, et al. Vaccine development throughout history (El desarrollo de la vacuna a lo largo de la historia). Cureus. 2021; doi ...

  7. Historia de la poliomielitis: línea cronológica de brotes y vacunas

    ... vaccine (Vacuna trivalente combinada contra sarampión, paperas y rubéola). JAMA. 1971;218:57. Klein NP. Licensed pertussis vaccine in the United States ...

  8. Hematología - Ensayos clínicos - Mayo Clinic

    REVOLUTION will be a multicenter registry enrolling approximately 2,500 patients. Additional patients limited to those with EGFR mutations may be enrolled ...

  9. Hematología - Ensayos clínicos - Mayo Clinic

    REVOLUTION will be a multicenter registry enrolling approximately 2,500 patients. Additional patients limited to those with EGFR mutations may be enrolled ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic ...